VEGI Human, His
Description
Introduction to VEGI Human, His
VEGI Human, His (Catalog No.: AP3724) is a recombinant human protein fused with a 21-amino acid histidine (His) tag at the N-terminus. Produced in E. coli, this non-glycosylated polypeptide consists of 201 amino acids (residues 72–251) and has a molecular mass of 22.7 kDa . It is purified using proprietary chromatographic techniques and provided as a sterile, filter-sterilized solution in a buffer system optimized for stability and bioactivity .
Biochemical Characteristics
The structural and compositional details of VEGI Human, His are summarized below:
| Parameter | Description |
|---|---|
| Molecular Mass | 22.7 kDa |
| Amino Acid Sequence | 201 residues (72–251 a.a.) |
| Buffer Composition | 20 mM Tris-HCl (pH 8.0), 50% glycerol, 1 mM DTT, 0.2 M NaCl |
| Protein Form | Single polypeptide chain |
| Purity | Purified via chromatographic methods (proprietary) |
This formulation ensures long-term stability, with glycerol acting as a cryoprotectant and DTT preventing oxidation .
Production and Purification
VEGI Human, His is synthesized in E. coli, leveraging bacterial expression systems for cost-effective production. The His tag facilitates affinity purification, enabling efficient separation and concentration of the recombinant protein . While specific chromatography methods are not disclosed, the use of Tris-HCl and NaCl suggests ion-exchange or size-exclusion chromatography steps to achieve high purity .
Research Applications
While direct experimental data from peer-reviewed studies are unavailable in the provided sources, the product’s design aligns with applications in:
-
Protein-protein interaction studies: The His tag enables immobilization on nickel- or cobalt-based resins.
-
Structural biology: Soluble recombinant proteins are critical for crystallization or NMR studies.
-
Functional assays: The buffer’s compatibility with enzymatic or binding assays (e.g., ELISA, SPR) is implied.
Limitations and Future Research
The absence of peer-reviewed studies in the provided sources highlights gaps in understanding VEGI Human, His’s functional roles or biophysical properties. Further research is needed to validate its utility in specific assays (e.g., cytokine signaling pathways) and compare its performance with non-tagged variants.
Product Specs
Product Science Overview
Vascular Endothelial Growth Inhibitor (VEGI), also known as Tumor Necrosis Factor Superfamily Member 15 (TNFSF15) or TNF-like ligand 1A (TL1A), is a potent anti-angiogenic cytokine. It plays a crucial role in inhibiting the formation of new blood vessels (angiogenesis), which is essential in various physiological and pathological processes, including cancer, inflammation, and wound healing .
The recombinant form of VEGI, particularly the human recombinant version with a His tag, is engineered to facilitate purification and detection. The His tag, typically a sequence of six histidine residues, allows for affinity purification using nickel or cobalt-based resins. This recombinant protein is expressed in host systems such as HEK293 cells, ensuring proper folding and post-translational modifications .
VEGI exerts its anti-angiogenic effects by binding to its receptor, Death Receptor 3 (DR3), on the surface of endothelial cells. This interaction triggers downstream signaling pathways that lead to apoptosis (programmed cell death) of endothelial cells, thereby inhibiting the formation of new blood vessels . This mechanism is particularly significant in the context of cancer, where inhibiting angiogenesis can starve tumors of the necessary blood supply for growth and metastasis.
VEGI has been implicated in various diseases characterized by abnormal angiogenesis. For instance, elevated levels of soluble TL1A (a form of VEGI) have been detected in the serum of patients with T-cell mediated autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease . These findings suggest that VEGI could be a potential therapeutic target for these conditions. Recent clinical studies have also indicated that anti-TL1A antibody treatment shows promise in managing inflammatory and autoimmune disorders .
The development of recombinant VEGI with a His tag has facilitated extensive research into its biological functions and therapeutic potential. The His tag allows for efficient purification and detection, enabling researchers to study the protein’s structure, function, and interactions in detail. This recombinant protein is also used in various assays to investigate its effects on endothelial cell proliferation, migration, and apoptosis .
